Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
ALLK

ALLK - Allakos Inc Stock Price, Fair Value and News

0.82USD-0.02 (-2.38%)Market Closed

Market Summary

ALLK
USD0.82-0.02
Market Closed
-2.38%

ALLK Stock Price

View Fullscreen

ALLK RSI Chart

ALLK Valuation

Market Cap

74.4M

Price/Earnings (Trailing)

-0.35

EV/EBITDA

-0.88

Price/Free Cashflow

-0.62

MarketCap/EBT

-1.35

ALLK Price/Sales (Trailing)

ALLK Profitability

Return on Equity

-206.23%

Return on Assets

-120.94%

Free Cashflow Yield

-160.28%

ALLK Fundamentals

ALLK Earnings

Earnings (TTM)

-214.4M

Earnings Growth (Yr)

-67.78%

Earnings Growth (Qtr)

-13.74%

Breaking Down ALLK Revenue

Last 7 days

3.7%

Last 30 days

-26.7%

Last 90 days

-19.8%

Trailing 12 Months

-82.2%

How does ALLK drawdown profile look like?

ALLK Financial Health

Current Ratio

4.11

ALLK Investor Care

Shares Dilution (1Y)

2.29%

Diluted EPS (TTM)

-2.46

Tracking the Latest Insider Buys and Sells of Allakos Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 28, 2024
radford harlan baird
sold
-87,934
1.01
-87,064
chief financial officer
Jun 07, 2024
tomasi adam
sold (taxes)
-27,718
1.12
-24,749
president
Jun 06, 2024
alexander robert
sold (taxes)
-42,778
1.14
-37,525
chief executive officer
Jun 04, 2024
radford harlan baird
sold (taxes)
-17,332
1.19
-14,565
chief financial officer
Mar 06, 2024
radford harlan baird
sold (taxes)
-43,391
1.35
-32,142
chief financial officer
Mar 05, 2024
tomasi adam
sold (taxes)
-68,244
1.44
-47,392
president
Mar 04, 2024
alexander robert
sold (taxes)
-104,947
1.48
-70,910
chief executive officer
Dec 04, 2023
tomasi adam
sold (taxes)
-40,135
2.5
-16,054
president
Dec 04, 2023
alexander robert
sold (taxes)
-61,882
2.5
-24,753
chief executive officer
Dec 04, 2023
paterson craig a.
sold (taxes)
-17,480
2.5
-6,992
chief medical officer

1–10 of 50

Which funds bought or sold ALLK recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 12, 2024
SG Americas Securities, LLC
sold off
-100
-39,000
-
-%
Jul 11, 2024
INDUSTRY VENTURES, L.L.C.
sold off
-100
-259,122
-
-%
Jul 10, 2024
CWM, LLC
added
1,241
-
-
-%
Jul 08, 2024
Douglas Lane & Associates, LLC
unchanged
-
-2,613
10,051
-%
Jul 01, 2024
Legal & General Group Plc
reduced
-57.36
-28,587
7,004
-%
Jul 01, 2024
BROWN, LISLE/CUMMINGS, INC.
unchanged
-
-221
189
-%
Jun 11, 2024
EverSource Wealth Advisors, LLC
new
-
501
501
-%
May 29, 2024
Opaleye Management Inc.
new
-
3,068,100
3,068,100
0.67%
May 17, 2024
Ikarian Capital, LLC
added
293
528,008
1,175,170
0.13%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.27
-21,362
8,510
-%

1–10 of 48

Are Funds Buying or Selling ALLK?

Are funds buying ALLK calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ALLK
No. of Funds

Unveiling Allakos Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jul 08, 2024
blackrock inc.
1.4%
1,267,129
SC 13G/A
Feb 14, 2024
deep track capital, lp
2.87%
2,510,736
SC 13G/A
Feb 14, 2024
logos global management lp
3.3%
2,900,000
SC 13G/A
Feb 14, 2024
citadel advisors llc
3.4%
6
SC 13G/A
Feb 12, 2024
price t rowe associates inc /md/
9.1%
7,920,708
SC 13G
Feb 12, 2024
price t rowe associates inc /md/
0.7%
638,102
SC 13G/A
Feb 02, 2024
rivervest venture fund iii, l.p.
0.0%
0
SC 13D/A
Jan 29, 2024
blackrock inc.
5.8%
5,116,088
SC 13G
Jan 26, 2024
deep track capital, lp
5.72%
5e+06
SC 13G
Jan 26, 2024
deep track capital, lp
2.87%
2,510,736
SC 13G/A

Recent SEC filings of Allakos Inc

View All Filings
Date Filed Form Type Document
Jul 08, 2024
SC 13G/A
Major Ownership Report
Jul 02, 2024
4
Insider Trading
Jun 28, 2024
144
Notice of Insider Sale Intent
Jun 25, 2024
8-K
Current Report
Jun 25, 2024
8-K
Current Report
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 07, 2024
144
Notice of Insider Sale Intent
Jun 06, 2024
144
Notice of Insider Sale Intent
Jun 06, 2024
4
Insider Trading

Peers (Alternatives to Allakos Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
47.5B
6.8B
-10.56% 2.15%
-7.97
6.94
-64.45% -224.75%
31.6B
2.0B
55.73% 23.15%
-95.16
15.77
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.3B
2.5B
2.83% -0.92%
79.38
6.6
13.74% 186.89%
14.4B
3.8B
3.06% 4.80%
19.28
3.81
8.58% 129.81%
MID-CAP
5.5B
107.9M
4.99% -8.71%
-10.01
48.09
54.84% -28.31%
5.0B
524.1M
-2.02% -21.56%
-11.97
9.53
394.93% 39.61%
4.0B
251.0M
15.33% 15.88%
-13.61
16.07
73.58% -86.73%
3.7B
240.7M
14.36% -14.84%
-7.76
12.77
-1.03% -213.92%
3.1B
813.8M
24.88% -44.36%
-1.8K
3.78
56.43% 98.83%
2.2B
996.6M
14.03% 101.23%
-5.58
2.23
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
12.68% 25.98%
30.67
4.86
60.38% -34.49%
628.7M
881.7K
20.30% 675.68%
-18.62
481.06
-77.61% 33.36%
287.1M
4.2M
22.55% 71.91%
-2.3
69.02
-66.30% 48.24%
18.5M
2.1M
-16.02% -80.80%
-0.8
7.61
-13.45% 69.54%

Allakos Inc News

Latest updates
Defense World21 hours ago
American Banking and Market News15 Jul 202404:01 pm
Seeking Alpha26 Jun 202407:00 am
InvestorPlace6 months ago

Allakos Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-27.2%177244283319350386419307346535621655684720441474500517535170185
  Current Assets-17.9%148180218252283309339222258452531576629669425458484500520154169
    Cash Equivalents-35.2%43.0066.0071.0067.0094.0087.0020582.0036.0015527420417020710415413641.0030936.0031.00
  Net PPE-48.0%17.0033.0035.0036.0038.0039.0040.0041.0044.0043.0040.0025.0014.008.007.008.008.008.008.009.009.00
Liabilities-2.0%73.0075.0062.0064.0070.0076.0074.0084.0086.0089.0097.0084.0068.0065.0027.0027.0022.0021.0021.0018.0017.00
  Current Liabilities-1.8%36.0037.0023.0024.0030.0030.0028.0037.0038.0040.0041.0034.0023.0022.0019.0020.0014.0013.0012.009.008.00
Shareholder's Equity-38.4%104169221255280310344223260445525571616654414447478496514152168
  Retained Earnings-6.4%-1,189-1,118-1,055-1,010-975-932-889-859-809-612-518-455-398-342-298-256-217-189-164-143-124
  Additional Paid-In Capital0.5%1,2931,2871,2771,2651,2561,2431,2341,0821,0701,0581,0431,0271,014997712703693685679295292
Shares Outstanding0.9%89.0088.0087.0087.0086.0085.0056.0055.0055.0055.0054.0054.00---------
Float----288---121---3,237---2,156---959-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-34.1%-32,541-24,268-29,479-32,594-30,139-46,786-26,128-32,770-174,287-65,377-46,435-49,782-46,259-34,415-35,823-25,072-18,614-19,111-16,199-14,423-13,279
  Share Based Compensation-39.1%6,21010,20310,5349,82110,6659,27310,73211,76111,39214,59512,49611,39712,35410,2067,9897,7627,4895,8653,9603,1052,834
Cashflow From Investing-55.3%9,02920,18931,5476,12135,318-71,4777,68778,05957,412-57,085113,08682,9494,288-137,525-15,29841,320115,400-249,862-91,50719,27810,120
Cashflow From Financing-132-1,070-1,458190141,27966.003478643,8138004,783274,8141,5261,7087898.00380,054138963
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ALLK Income Statement

2024-03-31
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses  
Research and development$ 34,824$ 33,078
General and administrative10,89811,968
Impairment of long-lived assets27,3470
Total operating expenses73,06945,046
Loss from operations(73,069)(45,046)
Interest income1,9952,678
Other expense, net(72)(36)
Net loss(71,146)(42,404)
Unrealized gain (loss) on investments(30)296
Comprehensive loss$ (71,176)$ (42,108)
Net loss per common share:  
Net loss per common share, basic$ (0.81)$ (0.49)
Net loss per common share, diluted$ (0.81)$ (0.49)
Weighted-average number of common shares outstanding:  
Weighted-average shares of common stock outstanding, basic88,04285,845
Weighted-average shares of common stock outstanding, diluted88,04285,845

ALLK Balance Sheet

2024-03-31
BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 43,060$ 66,440
Investments96,192104,354
Prepaid expenses and other current assets8,3829,095
Total current assets147,634179,889
Property and equipment, net17,36433,369
Operating lease right-of-use assets10,57724,136
Other long-term assets1,7376,216
Total assets177,312243,610
Current liabilities:  
Accounts payable15,7481,764
Accrued expenses and other current liabilities20,17334,814
Total current liabilities35,92136,578
Operating lease liabilities, net of current portion37,40838,215
Total liabilities73,32974,793
Contingencies (Note 8)
Stockholders’ equity:  
Preferred stock, $0.001 par value per share; 20,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued and outstanding as of March 31, 2024 and December 31, 202300
Common stock, $0.001 par value per share; 200,000 shares authorized as of March 31, 2024 and December 31, 2023; 88,544 and 87,750 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively8988
Additional paid-in capital1,293,4971,287,156
Accumulated other comprehensive gain (loss)2050
Accumulated deficit(1,189,623)(1,118,477)
Total stockholders’ equity103,983168,817
Total liabilities and stockholders’ equity$ 177,312$ 243,610
ALLK
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. In addition, Allakos Inc. is conducting preclinical studies for AK007, which polarizes tumor-associated myeloid cells and promotes anti-tumor immunity. The company was incorporated in 2012 and is headquartered in San Carlos, California.
 CEO
 WEBSITEallakos.com
 INDUSTRYBiotechnology
 EMPLOYEES123

Allakos Inc Frequently Asked Questions


What is the ticker symbol for Allakos Inc? What does ALLK stand for in stocks?

ALLK is the stock ticker symbol of Allakos Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Allakos Inc (ALLK)?

As of Tue Jul 16 2024, market cap of Allakos Inc is 74.38 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALLK stock?

You can check ALLK's fair value in chart for subscribers.

What is the fair value of ALLK stock?

You can check ALLK's fair value in chart for subscribers. The fair value of Allakos Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Allakos Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALLK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Allakos Inc a good stock to buy?

The fair value guage provides a quick view whether ALLK is over valued or under valued. Whether Allakos Inc is cheap or expensive depends on the assumptions which impact Allakos Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALLK.